yh533388ÒøºÓ

ÐÂÎÅÖÐÐÄ

    ¹ú×ÔÈ»Èȵã | Tissue CytometryÖúÁ¦¾ÞÊÉϸ°ûÑо¿

    ͼƬ


    ½èÖú¿Õ¼ä¶à×éѧ¼¼ÊõÑо¿Ë¼Â·¶Ô¾ÞÊÉϸ°û½øÐÐÑо¿ £¬ÊÇÄ¿½ñÈȵãµÄÇ°ÑØÆ«ÏòÖ®Ò» ¡£ÒòΪÂÑ°×ÖÊÊÇϸ°û¹¦Ð§µÄ×îÖÕµ£¸ºÕß £¬ÈçºÎ½âÎöÂÑ°×ÖÊ×éѧµÄʱ¿ÕÌØÒìÐÔ £¬ÊÇÁ˽⼲²¡±¬·¢Éú³¤¡¢×é֯ԭλµÄ΢Çé¿öÒìÖÊÐÔµÄÒªº¦ÒòËØ ¡£

    Tissue Cytometry¼¼Êõ×÷Ϊ¿Õ¼ä×éѧÑо¿ÌåϵµÄÒ»Ô± £¬ÔÚ¿Õ¼ä¶à×éѧÆÊÎöÖÐÕ¹ÏÖ³öÁËÆäÆæÌصÄÓÅÊÆ ¡£

    ͼƬ

    ¿Õ¼ä¶à×éѧÑо¿ÖÐÊ×ÏÈҪԭλ¿Õ¼äÐÅÏ¢µÄÍêÕû¿É¿¿ £¬Tissue Cytometry¼¼Êõ¼æÈÝͨÀý×éÖ¯ÇÐƬ £¬Ê×ÏÈÈ·±£ÁË×éÖ¯½á¹¹µÄÍêÕûÐÔ £¬Ê¹µÃÑо¿ÈËÔ±Äܹ»ÔÚ½Ó½ü×ÔȻ״̬ÏÂÊÓ²ìϸ°û¼äµÄÏ໥×÷Óà ¡£

    Æä´Î £¬Tissue Cytometry¼¼Êõͨ¹ý¾­µäµÄÏÔ΢³ÉÏñ¹â·ºÍ¶¨Î»ÅÄÉã»ñµÃÁ˸ßÇø·ÖÂʳÉÏñÄÜÁ¦ £¬ÎªÊ¶±ðºÍÁ¿»¯²î±ð×éÖ¯ÖоÖÊÆϸ°ûÒìÖÊÐÔÌṩÁË¿ÉÄÜ £»½áºÏÈí¼þµÄÇ¿´óÆÊÎö¹¦Ð§ £¬Ñо¿ÈËÔ±Äܹ»¶Ô´ó¹æÄ£µÄͼÏñÊý¾Ý½øÐпìËÙ׼ȷµÄ´¦Àí £¬´Ó¶øÔÚ·Ö×ÓˮƽÉϽÒʾ΢Çé¿öµÄÅÓ´óÐÔ ¡£ÕâÖÖ¼¼ÊõµÄÓ¦Óò»µ«¼ÓËÙÁ˶ԾÞÊÉϸ°ûµÄÑо¿Àí½â £¬Ò²Îª¿ª·¢ÐµÄÖÎÁÆÕ½ÂÔÌṩÁËÖØÒªµÄÐÅÏ¢ ¡£

    Cancer Cell

    ͼƬ

    ½¾ü¾üÒ½´óѧµÚÒ»Á¥ÊôÒ½Ôº£¨ÖØÇìÎ÷ÄÏÒ½Ôº£©È«¾üÁÙ´²²¡ÀíѧÑо¿Ëù±åÐÞÎäԺʿ¡¢Ê±Ó긱½ÌÊÚ¡¢Æ½éó·¼½ÌÊÚÍŶÓÁªºÏ½¾ü¾üÒ½´óѧµÚÒ»Á¥ÊôÒ½ÔºÄÔ½ºÖÊÁöҽѧÑо¿ÖÐÐÄ¡¢Éñ¾­Íâ¿ÆÀî·É¸±½ÌÊÚ¡¢»ªÖпƼ¼´óѧÎ人¹âµç¹ú¼ÒÑо¿ÖÐÐÄÕÅÖǺì½ÌÊÚÍŶӵÄÆîÊçºì¸±Ñо¿Ô±ÔÚCancer Cell(IF=50.3) Ðû²¼ÎÄÕ¡°Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalization¡± ¡£½ÒʾÁ˽ºÖÊĸϸ°ûÁöÖÐȱÑõ¾ÞÊÉϸ°ûµÄ±£´æºÍËüÃÇÔÚÖ×ÁöѪ¹ÜÕý³ £»¯ÖÎÁÆÖеÄDZÔÚ×÷Óà ¡£

    ͼƬ

    ±¾ÎÄ×÷Õß´ó×ÚÓ¦ÓÃÁËTissue Cytometry¼¼Êõ £¬ÀûÓÿ¹Ìå¶ÔÑù±¾Ö㬶à°Ð±êÂÑ°×½øÐÐÓ«¹â±ê¼Çºó £¬´ÓѪ¹ÜÐÎ̬ £¬Ö×Áö¼°Æ仵ËÀÇøÓòʶ±ð £¬È±Ñõ¿Õ¼ä΢Çé¿ö¹æÄ£¹¹½¨²¢Ì½Ë÷΢Çé¿öÖÐϸ°ûºÍѪ¹ÜµÄ×÷ÓùØϵ ¡£

    ÕâÖÖԭλÊý¾ÝУÑéµÄ˼· £¬²»µ«Ìî²¹ÁËԭλת¼×é¼¼ÊõµÄ¿Õ°× £¬Í¬Ê±½øÒ»²½ÌáÉýÁËÊý¾ÝµÄ¿É¿¿ÐÔ £¬¶ÔÎÄÕ¿´·¨½øÐÐÁËÇ¿ÓÐÁ¦µÄÖ§³Å ¡£

    Cancer Research

    ÖÐɽ´óѧÅíËë½ÌÊÚ/Ú÷¶°Ã÷½ÌÊÚÍŶÓÔÚCancer ResearchÉÏÔÚÏßÐû²¼ÌâΪ¡°Crosstalk between myeloid and B cells shapes the distinct microenvironments of primary and secondary liver cancer ¡±µÄÑо¿ÂÛÎÄ ¡£

    ¸ÃÑо¿Ê״δӵ¥Ï¸°û½Ç¶È¶ÔÔ­·¢ÐԺͼ̷¢ÐԸΰ©ÖеÄÃâÒß΢Çé¿ö½øÐÐÁËÉîÈë̽ÌÖ £¬½ÒʾÁ˲î±ðÀàÐ͵Ľ¬Ï¸°ûÓëËèϵϸ°ûÏ໥×÷Óý鵼ÃâÒßÒÖÖÆ΢Çé¿öµÄÏà¹Ø»úÖÆ ¡£Ö¤Ã÷ÁËBϸ°ûÊǸÎϸ°û°©( HCC )ºÍ½áÖ±³¦°©¸ÎתÒÆ( CRLM )΢Çé¿öÖеÄÖØÒªµ÷ÀíÒò×Ó ¡£

    ͼƬ

    ±¾ÎÄʹÓÃTissueGnostics¹«Ë¾TissueFAXS SpectraÈ«¾°¶à¹âÆ××é֯ɨÃ趨Á¿ÆÊÎöϵͳ¸ÎÔà×éÖ¯Ñù±¾½øÐжàÉ«Ó«¹âͼÏñÊÕÂÞ ¡£²¢ÇÒʹÓöàÖØÃâÒßÓ«¹â¼¼Êõ £¬Í¨¹ýAI Classifier¼¼Êõ»ñµÃ´ó×Ú×éÖ¯ÐÎ̬ѧÐÅÏ¢ £¬»¹½áºÏÁËTissue Cytometry¼¼ÊõÖо«×¼µÄµ¥Ï¸°ûʶ±ð¼¼Êõ ¡£

    ͨ¹ý¶àÖÖϸ°ûµÄ×é֯ԭλÐÅÏ¢ £¬Ö¤ÊµÁËcxcr3 + Bϸ°ûºÍTAMsͨ¹ýCXCR3-CXCL10ÖáµÄÏ໥×÷Óà £¬²¢Í¨¹ý½øÒ»²½ÊµÑé £¬·¢Ã÷ÔÚÌåÄÚ×è¶ÏCXCR3¿ÉÒÔÏÔÖøµØ¼õÈõBϸ°ûÏòÖ×ÁöµÄǨÒÆ £¬Ö¤Ã÷ÁËTAMsÔÚHCCÖÐļ¼¯CXCR3 + IgG½¬Ï¸°ûµÄÖØÒª×÷Óà ¡£

    Cellular and Molecular Biology

    Õã½­´óѧÐìæç½ÌÊÚ¡¢Õã´óÒ»¸½ÔºÎÀÇ¿¸±½ÌÊÚµÈÍŶÓÔÚCellular and Molecular BiologyÐû²¼ÌâΪ¡°Downregulation of N4-acetylcytidine modification in myeloid cells attenuates immunotherapy and exacerbates hepatocellular carcinoma progression¡±µÄÎÄÕ ¡£Í¨¹ý¼ì²â HCC ÃâÒßÖÎÁÆÆÚ¼äÖÖÖÖÃâÒßϸ°ûÑÇȺÖÐ ac4C ˮƽµÄ±ä¸ï £¬ÑéÖ¤ÁËac4CÐÞÊÎÔÚHCCÃâÒßÖÎÁÆÖеÄÖØÒª×÷Óà ¡£

    ͼƬ

    ×÷Õß½èÖúTissueCytometry¼¼Êõ £¬¾«È·Á¿»¯Ï¸°ûÃܶȺÍÂÑ°×±í´ïˮƽ £¬ÎªÑо¿ÕßÌṩÁ˹ØÓÚÖ×Áö΢Çé¿öÖÐϸ°ûÂþÑܺÍ״̬µÄÏêϸÐÅÏ¢ ¡£Í¨¹ý¶Ô¸Îϸ°û°©ÖÐac4C+CD11b+ϸ°ûÂþÑÜÃܶȵĶ¨Á¿ £¬ÆÊÎöÁËac4C+CD11b+ϸ°û±ÈÀýÓëHCC»¼ÕßÔ¤ºóÖ®¼äµÄ¹Øϵ £¬·¢Ã÷¸ß½þÈóµÄac4C+CD11b+ϸ°ûÓë¸üºÃµÄÔ¤ºóÕýÏà¹Ø ¡£

    ͼƬ


    ΢ÐÅÃñÖÚºÅ

    come-here
    ÍøÕ¾µØͼ